The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

Immune checkpoint blockade (ICB) therapy has achieved remarkable clinical benefit in melanoma. However, our understanding of biomarkers that predict response to ICB remained obscure. Here we systematically analyzed the association between somatic mutations profile and clinicopathologic information f...

Full description

Bibliographic Details
Main Authors: Hao Chen, Meng Yang, Qinghua Wang, Fengju Song, Xiangchun Li, Kexin Chen
Format: Article
Language:English
Published: Taylor & Francis Group 2019-08-01
Series:OncoImmunology
Subjects:
melanoma
immunotherapy
mutational signatures
col5a1
neoantigen quality
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1608132

Internet

http://dx.doi.org/10.1080/2162402X.2019.1608132

Similar Items